P
Priothera
We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic…
About Priothera
Priothera is a healthcare startup focused on improving the lives of patients suffering from blood cancers, specifically hematological malignancies. The company is developing an innovative immune modulator, mocravimod, to enhance the effectiveness of two types of treatments: allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and CAR-T cell therapy.
In simple terms, HSCT is a procedure that replaces a person's diseased bone marrow with healthy bone marrow stem cells. CAR-T cell therapy, on the other hand, is a type of treatment where a patient's T cells (a type of immune system cell) are changed in the lab so they will attack cancer cells.
Mocravimod works by reducing the movement of T-cells from lymphatic tissues, which helps to prevent a common complication of HSCT known as graft-versus-host disease (GvHD). At the same time, it enhances the benefits of the graft-versus-leukemia effect, which is the body's immune response against leukemia cells.
Priothera's business model revolves around the clinical development of mocravimod. The drug is currently under clinical development for use in combination with HSCT as a post-remission therapy for acute myeloid leukemia patients. The company generates revenue through the development, clinical trials, and potential future sales of mocravimod.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Dublin, Ireland
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 86.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, observatoire healthtech, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jun 2025 | $1.9M | — | Bpifrance | ↗ |
| DEBTDebt | Feb 2022 | $19M | — | European Investment Bank | — |
Growth signals
Latest recorded traffic for Priothera is 2.4K monthly website visits, up 727.6% over the last three months. Priothera's team grew 21.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
Earlybird Venture Capital
Fountain Healthcare Partners
HealthCap- TMTekla Capital Management
Series B and later1 investor entered at this stage
European Investment Bank
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Priothera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Priothera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.